The Papanicolaou Society of Cytopathology has developed a set of guidelines for respiratory cytology including indications for sputum examination, bronchial washings and brushings, CT-guided FNA and endobronchial ultrasound guided fine needle aspiration (EBUS-FNA), as well as recommendations for classification and criteria, ancillary testing and post-cytologic diagnosis management and follow-up. All recommendation documents are based on the expertise of committee members, an extensive literature review, and feedback from presentations at national and international conferences. The guideline documents selectively present the results of these discussions.
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5 study demonstrated problems with validation in nearly one half of antibodies tested using the Cellient cell block system (fixed in PreservCyt). 9 The antibodies had been previously validated for formalin-fixed., paraffin-embedded specimens. These findings bring into question the utility of methanol-fixed material for ICC and the probable need for revalidation of antibodies when methanol-fixed material is used.
Other types of specimens should be individually validated and require libraries of controls for optimum validation.
Microbiologic Culture
The lung is a favored site for localization of a number of infectious processes. These infectious agents can produce diffuse changes (lobar pneumonia) or more localized changes including abscesses and granuloma. A large number of infectious agents including viruses, fungi, bacteria, and mycobacteria may be responsible for pulmonary disease. Viral infections often have characteristic cytopathic effects facilitating their recognition. While viruses are rarely investigated by culture methods, other infectious agents are best definitively identified by a variety of culture techniques.
Culture of pulmonary specimens represents an important component of examination for many sputum, bronchoalveolar lavage and fine needle aspiration (FNA) specimens. Culture for acid fast bacilli, fungi and bacteria is often the most sensitive technique for establishing a specific diagnosis. Successful culture of a number of organisms requires specialized techniques and media. Optimal transport media have been identified for lymph node aspirates 1 and similar techniques and media can be used for pulmonary FNA specimens. ROSE examination may be helpful in selecting if and in what media material should be sent for culture. Accepted Article 7 based preparations, and formalin-fixed paraffin embedded cell block material. A recent study has questioned the reliability of the use of immunocytochemistry on methanol-fixed cell block material. 9 TTF-1 reacts with cells differentiating towards follicular thyroid epithelium, 25 some gastric adenocarcinomas, 26 and some pulmonary adenocarcinomas and small cell carcinomas. 27, 28 The sensitivity and specificity of TTF-1 for the separation of pulmonary adenocarcinoma from squamous cell carcinomas are approximately 85% 17, 29 and 97% 29 respectively. Napsin A has been shown to be reactive with pulmonary epithelium 20 and some neoplasms arising primarily within the ovary and other sites. 30 The sensitivity and specificity for napsin A in separating pulmonary adenocarcinomas from squamous cell carcinomas are 85% and 94% respectively. 17 p63 is a marker helpful in distinguishing squamous cell carcinomas from adenocarcinoma. 29, 31 While p63 is reactive in up to one third of pulmonary adenocarcinomas, 10 it remains useful for separating squamous carcinomas with a sensitivity and specificity of 100% and 85% respectively for the recognition of squamous cell carincoma. 31 p40 appears more specific for squamous cell carcinomas than p63 and some authors have advocated its replacing p63. 10 p40 has a sensitivity of 94% and a specificity of 96% for squamous cell carincoma. 29 Other authors have also found p40 to be superior to p63 for the identification of squamous cell carcinomas of the lung. [32] [33] [34] A number of authors have recommended panels of two to four immunohistochemical markers for the distinction of pulmonary adenocarcinoma from squamous cell carcinoma of the lung. 29, [31] [32] [33] [34] [35] [36] Potential panels include, (i) TTF-1, napsin A, p63, CK 5/6; (ii)TTF-1 and p40; (iii) napsin A and p40; or (iv)TTF-1 and p63. When performing immunohistochemistry for distinction of adenocarcinoma from squamous cell carcinoma it should be kept in mind that adequate material must be preserved for molecular testing.
Core biopsy should be encouraged for back-up, especially when ROSE shows that the sample cellularity Accepted Article 8 might be too low for analysis. 34 Kimbrell et al 37 addressed the issues concerning the utilization of immunocytochemistry in the sub-classification of non-small cell lung carcinomas.
Because diagnostic material must be saved for molecular testing, the use of double staining techniques should be considered when using immunocytochemistry for distinguishing squamous from adenocarcinomas. Johnson et al 38 has described a double staining method for TTF-1 and Napsin A.
Recommendation 2:
Pulmonary adenocarcinomas should be distinguished from squamous cell carcinomas. Use of immunohistochemical panels including some combination of TTF-1, napsin A, p63, p40 and CK 5/6 is recommended when significant cellular differentiation such as distinct keratinization is not seen. To preserve tissue for subsequent molecular testing, preferably one marker of adenocarcinoma and one of squamous cell carcinoma should be selected. Excessive immunostaining should be avoided to ensure preservation of cellular material for requested or anticipated molecular testing. The combination of TTF-1 and p40 appears optimal for separation of adenocarcinomas form squamous cell carcinoma.
Immunocytochemistry for Molecular Predictive Markers
While predictive testing for susceptibility to tyrosine kinase inhibitors is generally performed by molecular methods (FISH or PCR-based techniques), immunocytochemical methods exist for testing of some predictive markers. Immunocytochemical techniques have been used as initial tests which when positive, the specimen can be reflexed to a molecular laboratory for confirmatory testing. Antibodies directed against rearranged ALK, 39-41 ROS1, and mutated EGFR 42, 43 are three such markers. However, the utility of this approach may be limited. Antibodies directed against mutated EGFR are limited to detecting specific mutations (15 base pair deletions in exon 19 and p.L858R mutation in exon 21) and fail Accepted Article 9 to detect other EGFR mutations; while the ALK antibody may have false positive and false negative results. [43] [44] [45] [46] Immunohistochemistry appears to be a useful screening technique for ALK rearrangements with subsequent reflex of positive results to FISH analysis. This approach using reflex testing reduces overall cost as the percentage of pulmonary adenocarcinomas with ALK alterations is low. Currently, the Currently, immunohistochemistry may be a cost reduction technique for identification of molecular aberrations that occur at low frequency such as ROS1. A number of antibodies have been developed against ROS1 and detect the inappropriately expressed endogenous protein. Such inappropriate expression of the endogenous protein has been shown to occur in approximately 1.6% of non-small cell carcinomas of the lung. 47 Antibodies raised against ROS1 protein may represent a useful screening technique for ROS1 rearrangements with subsequent reflex of positive results for FISH testing. 48
Recommendation 3:
Immunocytochemical testing for mutated EGFR is not the preferred testing method for determination of tumor susceptibility to the associated tyrosine kinase inhibitors, but may be utilized in the setting of a limited volume sample when molecular testing cannot be performed.
Immunocytochemical testing for rearranged ALK may be used in place of FISH testing. 
PD-L1 Immunocytochemical Testing
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10 Expression of Programmed Death Ligand-1 (PD-L1) is a predictive marker for anti-PD-1/PD-L1 therapies.
PD-L1 is sometimes expressed in large amounts on cancer cells and allows their escape from immune surveillance and immune destruction. 49, 50 A new class of drugs target PD-1 or PD-L1 and are reported to have activity against some malignancies including non-small cell lung cancers. 51, 52 These drugs are useful for treatment of patients when standard chemotherapy has become ineffective. Nivolumab and pembrolizumab have been approved for treatment of non-small cell lung cancer, including both squamous cell carcinoma and adenocarcinoma. Section of the appropriate antibody clone for prediction of response to therapy depends on the drug selected. Testing protocols have been published. 52
Recommendation 4:
Immunohistochemical testing for anti PD-1/PD-L1 therapy appears appropriate for some patients who have become refractory to standard chemotherapy regiments. Selection of the antibody used for testing depends on the specific anti PD-1/PD-L1 drug used. Immunocytochemical testing for PD-L1 in non-squamous, non-small cell pulmonary carcinomas may aid in the selection of targeted therapy.
Detection of PD-L1 expressing carcinoma cells may indicate improved survival when patients are treated with Nivolumab therapy. 53 PD-L1 testing of cytology specimens has not undergone extensive validation in the published literature and specific recommendations fo its use for cytology material cannot be made at this time.
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PD-1/PD-L1 testing is performed at the discretion of the local oncology team and may be especially useful for patients non-responsive to tyrosine kinase inhibitor therapies. Treatment of squamous cell carcinoma with Nivolumab can be done without PD-L1 testing.
Immunocytochemical Testing for c-MET
Mesenchymal-epidermal transition (MET) receptor tyrosine kinase has been identified as a potential target for the treatment of non-small cell 54, 55 and some drug resistant small cell lung cancers. 56 c-MET overexpression may be important in the development of resistance to EGFR-tyrosine kinase inhibitors 54 and some chemotherapeutic agents used for treatment of small cell lung cancer. 56 MET amplification occurs in up to 20% of non-small cell carcinomas refractory to EGFR-tyrosine kinase therapy and some studies have suggested utility for the combined use of drugs resulting in MET and EGFR co-inhibition. 54 The role of immunohistochemistry for the prediction of response of c-MET inhibitors has not yet been elucidated, but c-MET therapy based on immunohistochemical staining has shown promise. 57 MET testing may have potential value for predicting progression on targeted therapy (EGFR) but such testing is for MET amplification and is performed by FISH.
Recommendation 5:
Currently, MET testing cannot be recommended for routine use, but such testing can be performed at the discretion of the local oncology team. 
Immunocytochemistry for the Identification and Classification of Metastatic Malignancies to the Lung
Diagnostic Cytopathology
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Metastatic disease is responsible for a significant percentage of lung nodules. While negative results of markers such as napsin A and TTF-1 may suggest a non-primary pulmonary adenocarcinoma, lack of staining for these markers does not exclude a lung origin, particularly in mucinous adenocarcinoma. A combination of cytomorphologic features and immunohistochemical reaction patterns is used to diagnose metastatic neoplasms. Differential cytokeratin staining patterns (CK7, CK20, and CK5/6) and specific lineage markers such as melan-A, HMB-45, prostatic specific antigen (PSA), leukocyte common antigen (LCA), p40, CDX-2, GATA-3, PAX-8, desmin, muscle specific actin (MSA), smooth muscle actin (SMA) and CD117 among others can be extremely helpful in the specific diagnosis of a metastatic neoplasm. Table I lists a selection of immunocytochemical markers helpful in the evaluation of metastatic neoplasms. Immunocytochemical testing of samples to determine tumor type or site of origin for metastases is a complex process with overlapping patterns of staining between pulmonary primaries and metastatic disease. For instance, some pulmonary adenocarcinomas may be CK20 positive (a finding often considered supporting a non-pulmonary origin). Similarly, CDX-2 a marker considered to support a gastrointestinal origin may be positive in some mucinous carcinomas of the lung. GATA-3, which usually supports a urothelial origin, may be expressed by some pulmonary squamous cell carcinomas. Thus, no single immunocytochemical staining result is definitively diagnostic for a specific type of neoplasm, but patterns of staining are helpful in assessing the organ of origin for metastatic disease.
Recommendation 6:
Selected panels of antibodies should be used to establish the origin and direction of differentiation in suspected metastatic disease to the lung. The precise panel of antibodies should be determined by 
Molecular Techniques for Predictive Testing Associated with Targeted Therapy
The advent of a number of targeted therapies for lung cancer has placed new responsibilities on pathologists to perform molecular studies used to identify patients likely to respond to such therapies.
Not only is the pathologist responsible for identifying which carcinomas should undergo testing, but he/she is responsible to ensure that adequate and representative material is present for ancillary testing. Presently, the majority of such targeted therapies are directed at adenocarcinomas (EGFR, ALK, and ROS1), but new therapies targeting squamous cell carcinomas are under development. The pathologist must make every attempt possible to obtain adequate tissue for molecular testing. 58, 59 Proper tissue acquisition and management requires good communication between pulmonologist, radiologist and pathologist. 10 ROSE can be very helpful in assuring adequate tissue is collected when sampling is performed under endobronchial ultrasound (EBUS) or computerized tomography (CT) guidance. Since EGFR, KRAS, ROS1, and ALK testing can be reliably performed on formalin fixed paraffin embedded cell block material, 10,60-63 ROSE can be very useful in triaging material for processing to cell block. 63 The choice of the appropriate specimen type for molecular testing remains controversial.
Studies have demonstrated that formalin fixed paraffin embedded cell block (CB) material is a satisfactory substrate for molecular testing 64 but cellularity of CBs remains a problem with up to 57% of CBs being acellular or of borderline cellularity for molecular testing. 65 Most studies have reported on the utility of formalin-sixed, paraffin-embedded surgical resection specimens or small biopsy specimens, but a number of studies have addressed the use of cytologic preparations. 66, 67 These studies reviewed the use of CBs, direct smears, and liquid based preparations. Current data indicates that a variety of 
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14 cytologic preparations yield molecular testing results similar to those achieved with histologic samples. [67] [68] [69] [70] In some cases, cytologic samples have been associated with detection rates for mutations higher than those obtained by histologic sampling methods. 70 Cell blocks have been shown to be comparable to core biopsies in some studies for detection of clinically important mutations. 71, 72 A significant number of studies have shown that smears and CBs are equivalent for molecular testing. 68, [73] [74] [75] In an analysis of 181 articles focusing on EGFR analysis in lung cancer, da Cunha Santos et al. 66 showed that cytologic techniques using an array of fixation and processing techniques yielded mutation detection rates similar if not superior to histologic material. Moreover, cell blocks, smears, and liquid based techniques were all useful for detection of clinically important mutations in non-small cell lung cancer. 66 The majority of organizations and authors recommend molecular testing of pulmonary adenocarcinoma for EGFR and ALK. 75, 76 In general, when tissue is limited, EGFR testing is prioritized and performed before ALK. 63, 75 Additional markers that may be tested in pulmonary adenocarcinomas include KRAS, ROS1, BRAF, RET, MET, neurotrophic tyrosine kinase receptor type 1 (NTRK1) and v-erb-b2 erythroblastic leukemia viral oncogene homolog2 (ERBB2). 76, 77 While no recommendations for prioritization of these markers have yet been published, some authorities recommend early performance of KRAS analysis. KRAS mutations appear to exclude mutations in EGFR and EML4-ALK and the KRAS gene product is present in the control pathway before EGFR and EML4-ALK, thus negating the impact of these latter two genes. With the recent FDA approval of crizotinib for treatment of ROS1 rearranged tumors, immunocytochemical or FISH testing for ROS1 rearrangements should now be performed following negative results for EGFR and ALK testing.
Molecular testing for pulmonary squamous cell carcinoma remains in its infancy with few markers yet having clinical utility. Potential target genes include: fibroblast growth factor receptor 1 (FGFR1) and the related amplification in FGFR2, FGFR3, and FGFR4. 78 Other potential targets are phosphatase and tensin
Next-Generation Sequencing and Molecular Analysis of Pulmonary Carcinoma
In an era of precision medicine with new emerging biomarkers guiding therapeutic decisions in lung cancer, there is an increasing need for a more comprehensive approach to generate a complete molecular profile for cytologic specimens. Clinical next-generation sequencing (NGS) has allowed for simultaneous screening of multiple genes in a massively parallel manner from cytologic samples using very small amounts of DNA. Several recent studies have described the utility of NGS mutational analysis in pulmonary cytopathology utilizing both aspiration cytology (CT-guided FNA and EBUS-guided FNA) [86] [87] [88] [89] [90] as well as exfoliative cytology (body cavity fluids and bronchoalveolar lavage) specimens. 89, 91, 92 The high analytical sensitivity of NGS platforms (approximately 5-10%) permits evaluation of samples with relatively low tumor fraction. 87, 91, 93, 94 One of the earlier studies utilizing NGS on cytologic specimens demonstrated the high sensitivity of NGS compared to conventional testing methods by using cells extracted from Papanicolaou stained smears of low tumor volume samples of bronchoalveolar lavage and pleural fluids. 91 NGS success rates do not vary significantly between aspiration and exfoliative cytology samples and NGS success rates of lung FNAs are similar to that of other sites. 89 The most common causes of NGS failure in lung cytologic specimens are related to insufficient DNA yield, due to overall low cellularity, or insufficient tumor cellularity, in cases with high numbers of nontumor background cells and/or where the tumor cells are heterogeneously distributed, frequently seen in EBUS FNA, samples obtained by brushing, or body cavity fluid samples. 88 Although aspiration cytology specimens usually provide inherently high tumor fraction due to lower numbers of background stromal components, they are frequently limited by the volume of tissue aspirated (overall cellularity) that dictates the quantitative DNA yield. 89, 93 Implementing measures such as ROSE for adequacy assessment and additional needle passes may improve the overall cellularity to meet the input DNA requirement for Page 18 of 30
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19 the NGS assay. 95 Also, tumor enrichment techniques by demarcating on the H&E stained cell block section or directly on the smear slides for macro/microdissection can improve the tumor fraction by eliminating background non-tumor cells, thereby reducing the chances of a false negative result. 96 Cell block preparations as well as direct smears and liquid-based cytology (LBC) have been successfully employed for NGS. [86] [87] [88] [89] [90] 92 The input DNA requirement for NGS analysis varies by testing platform but ranges between 10 ng for Ion Torrent PGM (Life Technologies, Carlsbad, CA) and 250 ng for Illumina (Illumina Inc, San Diego, CA) platforms. 97 Depending on the target capture method and the platform type, this roughly translates to approximately 100 to 1000 cells for Ion Torrent and 5000-15,000 cells for Illumina NGS. 98 There is no significant difference in NGS success rates between specimen preparations or cytological stains/fixatives. 88 The NGS sequencing performance metric (coverage depth, total number of reads, number of mapped reads and on-target reads, and variant calls) of cytologic smears and cell block preparations are comparable to that of FFPE histologic specimens. 88, 90 In addition, NGS has been successfully performed using DNA extracted from residual LBC samples of FNA and body fluid samples with significantly higher DNA yield from the LBC rinse than the matched cell block sections. 92 Molecular diagnostics in lung cytopathology has undergone a paradigm shift with the advent of NGS which allows for evaluation of multiple biomarkers in a single assay using minimal amounts of DNA. [97] [98] [99] In this changing landscape of precision medicine, the cytopathologist plays a critical role in triaging and selecting suitable material for successful implementation of NGS on lung cytologic specimens. However, one needs to keep in mind that NGS not only detects known driver mutations for specific targeted therapy, but will likely also identify passenger mutations and/or low level mutations in small subclonal populations, and variants of unknown significance (VUS), all of which need to be interpreted in the proper clinical context for subsequent clinical management. In the absence of "actionable" oncogenic mutations, these may have some relevance in the prospective enrollment of patients in pre-clinical or clinical trials for targeted therapy. 100, 101 
